Q4 2024 EPS Estimates for Kenvue Inc. Lifted by Analyst (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) – Analysts at William Blair boosted their Q4 2024 earnings estimates for Kenvue in a research note issued to investors on Tuesday, June 25th. William Blair analyst J. Andersen now forecasts that the company will post earnings of $0.30 per share for the quarter, up from their previous estimate of $0.29. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kenvue’s current full-year earnings is $1.17 per share.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. The business’s revenue was down 24.9% compared to the same quarter last year.

KVUE has been the topic of several other research reports. The Goldman Sachs Group began coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Citigroup reiterated a “neutral” rating and set a $21.00 target price on shares of Kenvue in a research report on Tuesday, May 28th. HSBC upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. Finally, Sanford C. Bernstein began coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.09.

Kenvue Stock Performance

Shares of KVUE opened at $18.59 on Thursday. The firm has a market cap of $35.60 billion and a PE ratio of 23.83. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average price of $19.24 and a 200-day moving average price of $20.01. Kenvue has a 12 month low of $17.75 and a 12 month high of $26.66.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.30%. The ex-dividend date of this dividend was Tuesday, May 7th. Kenvue’s dividend payout ratio is presently 102.56%.

Hedge Funds Weigh In On Kenvue

Several institutional investors have recently bought and sold shares of the company. Beaumont Financial Advisors LLC increased its stake in shares of Kenvue by 3.0% during the fourth quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock worth $377,000 after acquiring an additional 509 shares during the period. Pinnacle Bancorp Inc. increased its position in Kenvue by 51.3% during the 4th quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock worth $33,000 after purchasing an additional 526 shares during the period. Manchester Capital Management LLC raised its stake in shares of Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares in the last quarter. Tradition Wealth Management LLC lifted its holdings in shares of Kenvue by 2.8% in the 4th quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock valued at $458,000 after buying an additional 575 shares during the period. Finally, Dfpg Investments LLC boosted its stake in shares of Kenvue by 2.3% in the fourth quarter. Dfpg Investments LLC now owns 26,659 shares of the company’s stock valued at $567,000 after buying an additional 589 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.